David O. Nettleton
Novartis (United States)(US)
Publications by Year
Research Areas
Bacteriophages and microbial interactions, Bacterial Genetics and Biotechnology, Epigenetics and DNA Methylation, Pharmacogenetics and Drug Metabolism, Lipoproteins and Cardiovascular Health
Most-Cited Works
- → A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro(2008)198 cited
- → Medicinal Chemistry Profiling of Monocyclic 1,2‐Azaborines(2017)116 cited
- → Glucose-Induced Conformational Changes in Glucokinase Mediate Allosteric Regulation: Transient Kinetic Analysis(2006)90 cited
- → Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development(2011)54 cited
- → Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies☆(2010)53 cited
- → Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders(2023)50 cited
- → Genetics of Bacillus subtilis chemotaxis: isolation and mapping of mutations and cloning of chemotaxis genes(1983)48 cited
- → Fluorescently Labeled Analogues of Dofetilide as High-Affinity Fluorescence Polarization Ligands for the Human Ether-a-go-go-Related Gene (hERG) Channel(2007)44 cited
- → Identification of a PCSK9-LDLR disruptor peptide with in vivo function(2021)44 cited
- → Preclinical Pharmacology of CP-424,391, an Orally Active Pyrazolidinone-Piperidine Growth Hormone Secretagogue(2001)40 cited